Hematopoietic Stem Cell TransplantNCT07595146
Meaning-Centered Psychotherapy for Addressing Existential Distress of Patient/Caregiver Dyads Following Hematopoietic Stem Cell Transplantation: Feasibility and Acceptability
A study testing Meaning-Centered Psychotherapy in people with Hematopoietic Stem Cell Transplant, run by Mayo Clinic at 1 site in United States.
Trial summary
The purpose of this study is to learn whether Meaning-Centered Psychotherapy (MCP-Dyad) is practical, acceptable, and helpful to survivors and caregivers during recovery after stem cell transplant. MCP-Dyad is a meaning-focused support program. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hematopoietic Stem Cell Transplant
- What is being tested?
- Meaning-Centered Psychotherapy
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Dec 2026to 30 Apr 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Eligible patients and their caregivers must be adults (≥18 years)
- Patient must have undergone HSCT for a malignant blood cancer condition
- Caregiver must be the main support person (e.g., signed caregiving contract) for the HSCT patient
- Both the patient and their caregiver must be willing to participate in the study (dyads only)
- Be able to read, write, and speak in English
- Have access to a smartphone, computer, or tablet necessary for study participation and assessments. If a patient/caregiver dyad is interested in participating but does not have such a device, we will provide a Tracfone with smartphone capabilities for each member of the dyad
Who cannot join
- Patients undergoing HSCT for nonmalignant conditions
- Patients and caregivers with severe cognitive or psychiatric impairment that may affect informed consent/participation
- Prisoners, pregnant women, and institutionalized persons
- Patients with severe cognitive or psychiatric impairment that would affect informed consent or participation
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
Mayo Clinic
Rochester, Minnesota, 55905
Study Team, 507-422-5523, rstnursingresearch@mayo.edu
About this study
The purpose of this study is to learn whether Meaning-Centered Psychotherapy (MCP-Dyad) is practical, acceptable, and helpful to survivors and caregivers during recovery after stem cell transplant. MCP-Dyad is a meaning-focused support program. It is designed to help people stay connected to meaning, cope with difficult experiences, and communicate as a pair during recovery.
- Conditions
- Hematopoietic Stem Cell Transplant
- Being tested
- Meaning-Centered Psychotherapy, Usual Care
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Meaning-Centered PsychotherapyBehavioural
Survivor and caregiver dyads will participate in a seven-session, telehealth delivered Meaning-Centered Psychotherapy for Dyads (MCP-Dyad) program post-transplant.
Usual CareBehavioural
Survivor and caregiver dyads will receive standard resources and consultations for hematopoietic stem cell transplantation (HSCT) care, which include a joint educational class for patients and caregivers before and after treatment.
| Study group | Role | What they receive |
|---|---|---|
| Meaning-Centered Psychotherapy (MCP) Dyad | Experimental | The MCP-Dyad arm participants will meet with an MCP-Dyad interventionist to engage in didactic content, reflection, and discussion to teach participants how to apply four sources of meaning to their lives Receives: Behavioral: Meaning-Centered Psychotherapy |
| Usual Care | Active comparator | The standard of care arm will receive standard resources and consultations for HSCT care, which include a joint educational class for patients and caregivers before and after treatment. Receives: Behavioral: Usual Care |
What is being measured
The primary outcome is the main question the study is designed to answer.
Feasibility to accrue HSCT patient/caregiver dyads
Percentage of eligible caregivers approached who consent and enroll within 24 months.
Measured: 2 years
MCP-Dyad intervention completion
Percentage of patients and caregivers in the MCP-Dyad cohort who complete at least 5 out of 7 intervention sessions (benchmark: 70%).
Measured: End of treatment (approximately 14 weeks)
MCP-Dyad Feasibility rating from participants (Feasibility of Intervention Measure-FIM)
Percentage of patients and caregivers who rate MCP-Dyad as 4/5 or higher on the Feasibility of Intervention Measure (FIM) 4-item questionnaire (benchmark: 70%). Higher scores signify greater agreement with intervention feasibility.
Measured: End of treatment (approximately 14 weeks)
MCP-Dyad retention
Percentage of randomized dyads with both members completing follow-up assessments (benchmark: 75%).
Measured: End of treatment (approximately 14 weeks)
MCP-Dyad intervention fidelity and protocol delivery
Percentage of audited sessions meeting intervention fidelity standards and delivered per protocol based on fidelity assessments (benchmark: ≥80%)
Measured: End of treatment (approximately 14 weeks)
MCP-Dyad acceptability as rated on the Acceptability of Intervention Measure (AIM)
Percentage of patients and caregivers who rate the intervention as 4/5 or higher on the 4-item Acceptability of Intervention Measure (AIM) questionnaire (benchmark: 70%). Higher scores signify greater agreement with intervention acceptability.
Measured: End of treatment (approximately 14 weeks)
MCP-Dyad appropriateness as rated on the Intervention Appropriateness Measure (IAM)
Percentage of patients and caregivers who rate the intervention as 4/5 or higher on the 4-item Intervention Appropriateness Measure (IAM) questionnaire (benchmark: 70%). Higher scores signify greater agreement with intervention appropriateness.
Measured: End of treatment (approximately 14 weeks)
MCP-Dyad dyad-level retention outreach
Percentage of missed sessions or assessments that receive outreach within 2 days (benchmark: ≥85%).
Measured: End of treatment (approximately 14 weeks)
Secondary outcomes (12)
Change in survivor and caregiver health-related quality of life.
The impact of MCP-Dyad on patient and caregiver health-related quality of life will be assessed using the Functional Assessment of Cancer Therapy -Bone Marrow Transplant (FACT-BMT). The patient instrument is a multidimensional measure of quality of life in adult HSCT patients. Each item is rated from 0 (not at all) to 4 (very much) and is an assessment of symptoms over the past 7 days. Domains include social and family well-being, emotional well-being, functional well-being, and BMT-specific concerns. Higher scores overall indicate better quality of life.
Measured: Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention
Change in survivor and caregiver existential distress
The impact of MCP-Dyad on the patient and caregiver's meaning and purpose (increased meaning and purpose equivalent to less existential distress) will be measured using the 48-item Life Attitude Profile-Revised (LAP-R) instrument. It has six domains (purpose, coherence, life control, death acceptance, existential vacuum, goal seeking) that make up two subscales, the Personal Meaning Index and Existential Transcendence. Higher scores generally indicate a more positive attitude towards life.
Measured: Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention
Change in survivor and caregiver spiritual well-being
The impact of MCP-Dyad on the patient's and caregiver's spiritual well-being will be measured using the Functional Assessment of Chronic Illness Therapy Spiritual Well-being (FACIT-Sp) Scale. It has two subscales, one for faith and another for meaning/peace. Higher scores indicate greater spiritual well-being.
Measured: Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention
Change in Benefit Finding Scale (BFS) score
The impact of MCP-Dyad on benefit finding will be measured using a slightly modified version of the Benefit Finding Scale (BFS), a 17-item measure that captures positive life challenges resulting from adversity (e.g., personal priorities, acceptance, daily activities, family, world views, relationship, purpose). Higher scores indicate greater benefit finding.
Measured: Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention
Change in survivor and caregiver mutuality (quality of relationship)
The impact of MCP-Dyad on survivor and caregiver mutuality will be measured using Mutuality Scale (MS). The Mutuality Scale measures the positive quality of the relationship between the care recipient and the caregiver. Grounded in the concept of mutuality (degree of love, reciprocity, shared pleasurable activities, and shared values) in the patient/caregiver relationship. There is a four-domain structure with items rated from 0 (not at all) to 4 (a great deal) with question stems examining varies aspects of the relationship (e.g., how much do you enjoy spending time together). Higher overall scores indicate greater mutuality.
Measured: Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention
Change in dyadic adjustment (couples only)
The impact of MCP-Dyad in couples will be measured using the Revised Dyadic Adjustment Scale (RDAS). The RDAS is a self-report measure of relationship quality in couples. It assesses dyadic consensus, dyadic satisfaction, and dyadic cohesion to give an overall index of marital quality. The rating scale is 0 (always disagree) to 5 (always agree). Higher overall scores indicates greater relationship satisfaction.
Measured: Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention
Change in illness-related communication
The change in illness-related communication will be measured using the Social Constraints Scale. This scale measures the extent to which individuals perceive their social environment, particularly close relationships, as a limiting or discouraging their ability to express thoughts and feelings related to a stressful experience. Items are rated from 1(never) to 4 (very often). Higher scores are equivalent to more social constraints in the relationship.
Measured: Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention
Change in Communal Coping Domains score
The Communal Coping Domains instrument assesses how patients and caregivers manage health-related behavior change, particularly in the context of health threats by measuring shared perceptions, confidence, and behaviors. There are three tailored subscales: use of communal coping (how frequently dyads use joint efforts to manage health threats), how confident the dyad is in working together to manage health, and beliefs about communal coping strategies. Responses for the use of the communal coping domain range from 1(never) to 5 (very often), and responses for the couple efficacy and outcome efficacy range from 0 (not at all) to 10 (very much). Higher overall scores indicate greater confidence in patient/caregiver coping strategies.
Measured: 8 weeks post-intervention
Change in survivor and caregiver needs/distress
The impact of MCP-Dyad on the survivor and caregiver's needs/distress will be measured using the Cancer SupportSource Survivors: CCS-15+ and the CancerSupportSource-Caregiver: CCS-Caregiver-18+ instruments. Survivors and caregivers will rate their level of concern from 0 (not at all) to 4 (very serious concern). Questions for survivors focus on emotional well-being, symptom burden \& impact, body image \& healthy lifestyle, health care team communication, relationships \& intimacy. Questions for caregivers focus on 5 areas of concern (emotional well-being, survivor well-being, caregiving tasks, finances, and healthy lifestyle) and areas of desired support. A total score for distress is recommended based on 18 items.
Measured: Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention
Change in survivor and caregiver psychological distress
The impact of MCP-Dyad on psychological distress will be measured using 2 anxiety and 2 depression questions from the CCS-15+ and the CCS-Caregiver-18+. These questions have established clinical cut offs. Scores range from 0 to 8. Survivor scores of 3 or above signify clinically significant anxiety or depression. Caregiver anxiety scores of 4 and above, and depression scores of 3 or above, indicate clinically significant distress.
Measured: Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention
Change in Dyadic Relationship Scale score
The Dyadic Relationship Scale is a brief dyadic measure assessing positive dyadic interaction and negative dyadic strain from both caregiver and care recipient perspectives. The caregiver version includes 11 items and the care recipient version includes 10 items, with two subscales: positive dyadic interaction and negative dyadic strain.
Measured: Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention
Change in interdependence of survivor and caregiver
The Inclusion of Other in the Self Scale is a single-item pictorial measure of perceived relationship closeness and self-other overlap. Respondents select one of seven increasingly overlapping circle pairs to represent their relationship with a specified other person, with higher scores indicating greater perceived closeness.
Measured: Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 May 2026
- Study start1 Dec 2026 (estimated)
- Primary completion28 Feb 2028 (estimated)
- Study completion30 Apr 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hematopoietic Stem Cell TransplantStudies of the same condition, open and under way.
- More trials run by Mayo ClinicThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Mayo Clinic
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Natalie S. McAndrew, PhD, RN, Mayo Clinic
- Investigators
- Natalie McAndrew, PhD, RN, Principal investigator, Mayo Clinic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07595146
- Sponsor's protocol ID
- 26-005192
- Status last verified
- Aug 2026
- First submitted
- 12 May 2026
- Last updated
- 12 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Meaning-Centered Psychotherapy for Addressing Existential Distress of Patient/Caregiver Dyads Following Hematopoietic Stem Cell Transplantation: Feasibility and Acceptability
- ClinicalTrials.gov ID
- NCT07595146
- Acronym / sponsor ID
- 26-005192
- Conditions
- Hematopoietic Stem Cell Transplant
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Mayo ClinicUniversity, hospital or other
- Study start
- 1 Dec 2026 (estimated)
- Primary completion
- 28 Feb 2028 (estimated)
- Study completion
- 30 Apr 2028 (estimated)
- First posted
- 19 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to learn whether Meaning-Centered Psychotherapy (MCP-Dyad) is practical, acceptable, and helpful to survivors and caregivers during recovery after stem cell transplant. MCP-Dyad is a meaning-focused support program. It is designed to help people stay connected to meaning, cope with difficult experiences, and communicate as a pair during recovery.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Meaning-Centered Psychotherapy (MCP) Dyad | Experimental | Behavioral: Meaning-Centered PsychotherapyThe MCP-Dyad arm participants will meet with an MCP-Dyad interventionist to engage in didactic content, reflection, and discussion to teach participants how to apply four sources of meaning to their lives |
| Usual Care | Active comparator | Behavioral: Usual CareThe standard of care arm will receive standard resources and consultations for HSCT care, which include a joint educational class for patients and caregivers before and after treatment. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Eligible patients and their caregivers must be adults (≥18 years)
- Patient must have undergone HSCT for a malignant blood cancer condition
- Caregiver must be the main support person (e.g., signed caregiving contract) for the HSCT patient
- Both the patient and their caregiver must be willing to participate in the study (dyads only)
- Be able to read, write, and speak in English
Key exclusion criteria (4 listed)
- Patients undergoing HSCT for nonmalignant conditions
- Patients and caregivers with severe cognitive or psychiatric impairment that may affect informed consent/participation
- Prisoners, pregnant women, and institutionalized persons
- Patients with severe cognitive or psychiatric impairment that would affect informed consent or participation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Meaning-Centered PsychotherapySurvivor and caregiver dyads will participate in a seven-session, telehealth delivered Meaning-Centered Psychotherapy for Dyads (MCP-Dyad) program post-transplant. | Behavioural | Meaning-Centered Psychotherapy (MCP) Dyad |
| Usual CareSurvivor and caregiver dyads will receive standard resources and consultations for hematopoietic stem cell transplantation (HSCT) care, which include a joint educational class for patients and caregivers before and after treatment. | Behavioural | Usual Care |
Primary outcome
Feasibility to accrue HSCT patient/caregiver dyads
Time frame: 2 years
Percentage of eligible caregivers approached who consent and enroll within 24 months.
MCP-Dyad intervention completion
Time frame: End of treatment (approximately 14 weeks)
Percentage of patients and caregivers in the MCP-Dyad cohort who complete at least 5 out of 7 intervention sessions (benchmark: 70%).
MCP-Dyad Feasibility rating from participants (Feasibility of Intervention Measure-FIM)
Time frame: End of treatment (approximately 14 weeks)
Percentage of patients and caregivers who rate MCP-Dyad as 4/5 or higher on the Feasibility of Intervention Measure (FIM) 4-item questionnaire (benchmark: 70%). Higher scores signify greater agreement with intervention feasibility.
MCP-Dyad retention
Time frame: End of treatment (approximately 14 weeks)
Percentage of randomized dyads with both members completing follow-up assessments (benchmark: 75%).
MCP-Dyad intervention fidelity and protocol delivery
Time frame: End of treatment (approximately 14 weeks)
Percentage of audited sessions meeting intervention fidelity standards and delivered per protocol based on fidelity assessments (benchmark: ≥80%)
MCP-Dyad acceptability as rated on the Acceptability of Intervention Measure (AIM)
Time frame: End of treatment (approximately 14 weeks)
Percentage of patients and caregivers who rate the intervention as 4/5 or higher on the 4-item Acceptability of Intervention Measure (AIM) questionnaire (benchmark: 70%). Higher scores signify greater agreement with intervention acceptability.
MCP-Dyad appropriateness as rated on the Intervention Appropriateness Measure (IAM)
Time frame: End of treatment (approximately 14 weeks)
Percentage of patients and caregivers who rate the intervention as 4/5 or higher on the 4-item Intervention Appropriateness Measure (IAM) questionnaire (benchmark: 70%). Higher scores signify greater agreement with intervention appropriateness.
MCP-Dyad dyad-level retention outreach
Time frame: End of treatment (approximately 14 weeks)
Percentage of missed sessions or assessments that receive outreach within 2 days (benchmark: ≥85%).
12 secondary outcomes
Change in survivor and caregiver health-related quality of life.
Time frame: Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention
Change in survivor and caregiver existential distress
Time frame: Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention
Change in survivor and caregiver spiritual well-being
Time frame: Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention
Change in Benefit Finding Scale (BFS) score
Time frame: Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention
Change in survivor and caregiver mutuality (quality of relationship)
Time frame: Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention
Change in dyadic adjustment (couples only)
Time frame: Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention
Change in illness-related communication
Time frame: Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention
Change in Communal Coping Domains score
Time frame: 8 weeks post-intervention
Change in survivor and caregiver needs/distress
Time frame: Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention
Change in survivor and caregiver psychological distress
Time frame: Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention
Change in Dyadic Relationship Scale score
Time frame: Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention
Change in interdependence of survivor and caregiver
Time frame: Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Hematopoietic Stem Cell Transplant
Not yet recruitingObservational study
Prevalence and Development of Liver Dysfunction in Hematopoietic Stem Cell Transplant
Hematopoietic Stem Cell Transplant
RecruitingEarly Phase 1
HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT
Hematologic Malignancy
Active, not recruitingPhase 2
Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia
Adult Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
RecruitingObservational study
Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant
Leukemia, Lymphoma
Enrolling by invitationPhase 2
Thiotepa + TBI + Fludarabine + Etoposide for Allo-HSCT in Patients With R/R or High-risk Acute Leukemia
Acute Leukemia, High Risk, Acute Leukemia Refractory
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Natalie McAndrew, PhD, RN principal investigator
Mayo Clinic
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Meaning-Centered Psychotherapy in people with Hematopoietic Stem Cell Transplant, run by Mayo Clinic at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 12 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Study Team (507-422-5523, rstnursingresearch@mayo.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Feasibility to accrue HSCT patient/caregiver dyads (time frame: 2 years). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Aug 2026.